Medical News

RSS

Philips announces voluntary recall of 5,400 HeartStart FR2+ automated external defibrillators

Philips announced today that it is voluntarily recalling approximately 5,400 HeartStart FR2+ automated external defibrillators (AEDs). This recall is being conducted due to the possibility of a memory chip failure that may render the device inoperable.

1 Oct 2009

Mayo study reveals infliximab reduces the need for colectomy

A new study led by Mayo Clinic researchers has found that ulcerative colitis patients had a 41 percent reduction in colectomy after a year when treated with infliximab, according to a study published in the October 2009 issue of Gastroenterology.

1 Oct 2009

Health care reform bill in Finance Committee could be finalized Friday

The Senate Finance Committee is preparing to finalize a health care reform bill while Democratic leaders are signaling that floor consideration will follow quickly.

1 Oct 2009

People with rare mutations of gene MUTYH at increased risk of bowel cancer

CANCER RESEARCH UK funded scientists have found that people who carry rare mutations within both copies of a gene called MUTYH are 28 times more likely to develop bowel cancer compared to the general population, according to a study in the Journal of Clinical Oncology.

1 Oct 2009

UMDNJ's University Hospital agrees to pay $8.3M to settle allegations

The University of Medicine and Dentistry of New Jersey (UMDNJ) has agreed to pay the government $8.3 million to settle allegations that it illegally paid kickbacks to cardiologists and caused the submission of false claims to Medicare, the Justice Department announced today.

1 Oct 2009

New software to detect multiple sclerosis before brain damage occurs

Researchers of the Unit for Systems Biology of the University of Jaén, led by Francisco J. Esteban, are developing a software for clinical use to detect multiple sclerosis even before the typical brain damage of this neurodegenerative disease appear. In order to do so, this scientific multidisciplinary team is calculating the fractal dimension of the brain images registered on magnetic resonance imaging.

1 Oct 2009

Orexigen's Empatic Phase 2b results demonstrate weight loss

Orexigen Therapeutics, Inc. today announced that its 24-week, Phase 2b trial for Empatic(TM) (bupropion SR/zonisamide SR), the Company's second late stage investigational combination drug for the treatment of obesity, met its primary efficacy endpoint by demonstrating statistically significantly greater weight loss for both Empatic doses compared to monotherapies and placebo.

1 Oct 2009

Epigentek Group releases SuperSense Methylated DNA Quantification kit

Epigentek Group Inc. today announced that it released the SuperSense(TM) Methylated DNA Quantification Kit to complete its line of methylated DNA quantification products. The SuperSense(TM) kit fluorometrically measures global DNA methylation shifts.

1 Oct 2009

HRA Pharma launches its new generation emergency contraceptive in Europe

HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.

1 Oct 2009

GSK allowed access to DiscoveRx' PathHunter ß-Arrestin parental cell lines and reagents

DiscoveRx Corp. announced today the signing of a global agreement with GSK, a leading pharmaceutical company, to provide access to its PathHunter™ ß-Arrestin parental cell lines, clones and associated reagents for use in GSK’s internal GPCR Screening and Profiling efforts.

1 Oct 2009

Catalyst Pharmaceutical Partners to continue development of CPP-109 drug

Catalyst Pharmaceutical Partners, Inc. today announced that the Company will continue to develop CPP-109 (Catalyst's version of vigabatrin) for the treatment of cocaine and methamphetamine addiction.

1 Oct 2009

VeriChip to commence Phase II development of an in vivo glucose-sensing RFID microchip

VeriChip Corporation and its development partner RECEPTORS LLC, a technology company whose AFFINITY by DESIGN chemistry platform can be applied to the development of selective binding products, announced today that VeriChip plans to fund its existing development partnership with RECEPTORS to launch Phase II development of an in vivo glucose-sensing RFID microchip.

1 Oct 2009

Advaxis announces Phase I trial results of its ADXS11-001 therapeutic cancer vaccine

The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc. (OTCBB: ADXS), the company that pioneered the live, attenuated Listeria monocytogenes (Lm) vaccine, has shown thirty-six (36) month survival in three (3) of the thirteen (13) evaluable patients treated with Advaxis’ therapeutic cancer vaccine, indicating the possibility of persistent immune protection.

1 Oct 2009

Clinical study results of prostate cancer patients treated with CyberKnife Radiosurgery released

Accuray Incorporated, a global leader in the field of radiosurgery, announced today publication of results from a study of early stage prostate cancer patients treated with CyberKnife Radiosurgery.

1 Oct 2009

New website launched provides details on breast cancer risks faced by younger women

A website launched to coincide with National Breast Cancer Awareness Month, at www.earlyactawareness.org, provides a powerful focal point for efforts to pass the EARLY Act.

1 Oct 2009

First prescription foam formulation of benzoyl peroxide available

Onset Therapeutics, a specialty pharmaceutical company focused on dermatology, announced today the commercial availability of BenzEFoam (benzoyl peroxide) 5.3% Emollient Foam, the first prescription foam formulation of benzoyl peroxide.

1 Oct 2009

Health Canada approves VIBATIV for treating complicated skin and skin structure infections

Astellas Pharma Canada, Inc. announced today that Health Canada has approved VIBATIV(TM) (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

1 Oct 2009

Phase 2 study of PH20 with regular human insulin confirms faster insulin absorption

Halozyme Therapeutics, Inc. today announced additional Phase 2 results that demonstrated faster insulin absorption and increased peak insulin concentrations in type 1 diabetic patients after co-administration of its recombinant hyaluronidase enzyme (rHuPH20 or PH20) with Humulin® R (regular human insulin), a mealtime insulin.

1 Oct 2009

NCI selects Integral Molecular to map epitopes for monoclonal antibodies

Integral Molecular, Inc. has been selected by the National Cancer Institute (NCI) to map epitopes for monoclonal antibodies directed against cancer biomarkers. Protein targets of interest to the Clinical Cancer Proteomics community will be analyzed using Shotgun Mutagenesis Mapping technology to identify amino acids that are essential for antibody binding, allowing the discovery and characterization of cancer-specific biomarkers.

1 Oct 2009

Talyst collaborates with healthcare consultancy to provide implementation services

Talyst, a leader in pharmacy automation systems, announced today a partnership with RXinnovate, a healthcare consultancy, to offer top-of-the-line implementation services to Talyst's clients in the acute care industry.

1 Oct 2009

Medical News

Philips announces voluntary recall of 5,400 HeartStart FR2+ automated external defibrillators

Mayo study reveals infliximab reduces the need for colectomy

Health care reform bill in Finance Committee could be finalized Friday

People with rare mutations of gene MUTYH at increased risk of bowel cancer

UMDNJ's University Hospital agrees to pay $8.3M to settle allegations

New software to detect multiple sclerosis before brain damage occurs

Orexigen's Empatic Phase 2b results demonstrate weight loss

Epigentek Group releases SuperSense Methylated DNA Quantification kit

HRA Pharma launches its new generation emergency contraceptive in Europe

GSK allowed access to DiscoveRx' PathHunter ß-Arrestin parental cell lines and reagents

Catalyst Pharmaceutical Partners to continue development of CPP-109 drug

VeriChip to commence Phase II development of an in vivo glucose-sensing RFID microchip

Advaxis announces Phase I trial results of its ADXS11-001 therapeutic cancer vaccine

Clinical study results of prostate cancer patients treated with CyberKnife Radiosurgery released

New website launched provides details on breast cancer risks faced by younger women

First prescription foam formulation of benzoyl peroxide available

Health Canada approves VIBATIV for treating complicated skin and skin structure infections

Phase 2 study of PH20 with regular human insulin confirms faster insulin absorption

NCI selects Integral Molecular to map epitopes for monoclonal antibodies

Talyst collaborates with healthcare consultancy to provide implementation services

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Latest News